Promega Corporation

06/15/2026

Lysosomes must move to do their job of breaking down waste and recycling nutrients. But what tells them when to stop? Researchers have identified the long-missing "off switch" for lysosome dispersal, a discovery that could help us develop treatments for lysosomal storage diseases and neurodegeneration.

Lysosomes must move to do their job—but what tells them when to stop? Researchers have identified the long-missing "off switch" for lysosome...

06/10/2026

Nevin Springs now features a 720-foot boardwalk overlooking the habitat's namesake artesian springs. Read why Promega invested in public access to a rare wetland ecosystem that was previously unreachable. https://www.promegaconnections.com/nevin-springs-boardwalk/

Nevin Springs now features a boardwalk providing access to the hidden springs, which flow year-round in this rare wetland ecosystem.

06/09/2026

A devastating virus threatens cowpea crops by hijacking one of the plant's own essential proteins. Natural mutations may hold the key to resistance. Learn how researchers mapped the 3D structure of the cowpea eIF4E family to build a roadmap for breeding virus-resistant cultivars in our latest blog.

Learn how researchers mapped the 3D structure of the cowpea eIF4E family to build a roadmap for breeding virus-resistant cultivars in our latest blog.

06/05/2026

Metabolic disease is complex, and so is studying it. In our latest blog, we explore how researchers are using Promega's bioluminescent toolkit to capture a fuller picture of metabolic dysfunction.

Read the full post to see how these tools are shaping the future of metabolism research. https://ow.ly/vksS50Z86W9

06/02/2026

Don't see your method in the library? Our team can build it for you.

Our Field Support Scientists work directly with KingFisher® users to develop and fine-tune Maxwell® HT protocols for specific sample types, throughput requirements and downstream applications at no additional cost. Whatever your workflow, we can help you find or build the right solution.

Talk to a Field Support Scientist: https://ow.ly/jyFM50YMSKA

06/02/2026

What if you could screen 100,000+ compounds for a neurological disease target — without sacrificing the biology that makes your results meaningful? That's what the Endo-GeneScreen platform set out to do. Check out our latest blog post to see how it works. https://ow.ly/h2AG50Z6ngB

05/22/2026

How do you fine-tune a crop gene without adding foreign DNA?

In a recent Nature Biotechnology study, researchers screened over 30,000 cis-regulatory mutations in sorghum and found small, nontransgenic edits that outperform traditional transgenic enhancers at driving gene expression.

A new study uses a massively parallel reporter assay in sorghum to map over 30,000 cis-regulatory mutations, revealing compact CRISPR edits that...

05/19/2026

Every ADC has multiple mechanisms working at once: payload delivery, Fc effector activity, and bystander killing. Understanding which mechanisms are driving efficacy is what separates a promising candidate from a pipeline risk.

That's where functional assays matter most. Tools that measure internalization efficiency, cytotoxicity, and Fc receptor engagement give development teams the mechanistic picture needed to make confident go/no-go decisions earlier.

Did you miss us at or want to learn more about ADC pipeline tools?

See how we support ADC development from target validation through functional screening: https://ow.ly/sJGY50YS0g3

05/14/2026

What if a drug could sneak past the cell membrane in disguise and then recruit a protein-disposal system no drug has ever targeted before?

A new Nature Chemical Biology paper describes exactly that. We break down the science in our latest blog: https://ow.ly/GtQ650YZzYi

05/11/2026

Vepdegestrant, the first approved PROTAC therapeutic for ESR1-mutated ER+/HER2– advanced breast cancer, received FDA approval on May 1, 2026. It marks a significant advancement in targeted protein degraders, demonstrating a new drug development approach focused on protein degradation rather than inhibition, with broader implications for future therapies in challenging cancer types.

Vepdegestrant, the first approved PROTAC therapeutic for ESR1-mutated ER+/HER2– advanced breast cancer, received FDA approval on May 1, 2026.